References 1 KFF, November 2025 2 KFF, November 2025 3 Beth Israel Deaconess Medical Center, November 2024 4 Baylor Scott & White Health, May 2026 5 Tufts Medicine, August 2025 6 Cornell Chronicle, September 2025 7 Curion, March 2026 8 WSJ, GLP-1 Users Are Taking a Bite Out of the Restaurant Business, May 13, 2026 9 Northwestern Now, November 2024 10 Northwestern Now, November 2024 For more information, visit harmelin.com, or connect with us on LinkedIn or Facebook.
Sleep and stress management Poor sleep amplifies pain perception through multiple mechanisms, including increased cortisol, reduced endogenous opioid activity, and impaired glymphatic clearance of inflammatory mediators
Adjust the maintenance block to match your goals and budget
In combination with low-dose GLP-1s, we believe the clinical benefit increases even more, with higher levels of adherence to GLP-1s, and we are confident that by pivoting to this approach, we will capitalize on the success of GLP-1s and set Allurion up for long-term success. The company also announced that it has submitted its protocol for a prospective, multi-centre study on the combination of the Allurion Program with a low-dose of GLP-1 for weight loss while maintaining muscle mass and increasing GLP-1 adherence to Institutional Review Boards (IRBs) in Europe for approval
Early-phase human trials describe significant weight-related endpoint changes, alterations in energy expenditure markers, and modulation of glucose homeostasis indicators
SmPCs for all of these medicines are available on the emc, and patient-facing information can be found on the NHS medicines pages
